OABIW — OmniAb, Inc.

OmniAb (OABIW) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $14.4 million, up from $4.2 million in Q1 2025, primarily driven by higher milestone revenue from partner programs.
• Operating Expenses: Decreased slightly to $22.3 million from $23 million, attributed to lower personnel and outside service costs. A noncash write-off of $2.9 million impacted the figures.
• Net Loss: $7.7 million ($0.06 per share), improved from a net loss of $18.2 million ($0.17 per share) in the prior year. Excluding the write-off, the adjusted loss would be $0.04 per share.
• Cash Position: Ended Q1 with $49.1 million in cash.
• Active Partners: Maintained at 107, with a balanced mix of discovery stage companies, large pharma, and academic institutions.

2. Strategic Updates and Business Highlights:

• Technology Advancements: Continued progress in partner programs, with 409 active programs and 32 in clinical stages. Notable advancements include two OmnidAb-derived programs entering human trials.
• New Technologies: The launch of OmniUltra, a transgenic chicken platform producing ultra-long CDRH3 antibodies, is expected to open new markets and enhance partner interest.
• xPloration Platform: Strong interest in this high-throughput single B-cell screening platform, which leverages AI and machine learning, is anticipated to diversify revenue streams.

3. Forward Guidance and Outlook:

• Revenue Guidance for 2026: Revised upward to $28 million to $33 million, reflecting strong Q1 performance and additional milestones achieved.
• Operating Expenses: Expected to be between $83 million and $88 million, influenced by the noncash impairment charge. Cash operating expenses remain unchanged at $50 million to $55 million.
• Year-End Cash Projection: Anticipated to end 2026 with cash and equivalents in the range of $33 million to $38 million.

4. Bad News, Challenges, or Points of Concern:

• Attrition: While the number of active partners remained stable, there was attrition offsetting new licenses, which is a normal part of the business.
• Market Headwinds: Some partners in the industry are facing challenges, particularly in early-stage biotech, which could impact future program starts.
• Dependence on Milestones: Revenue is largely milestone-driven, which can be variable and lumpy, posing risks to consistent revenue flow.

5. Notable Q&A Insights:

• Milestones and ASCO Data: Milestones are generally linked to clinical events rather than data disclosures, but upcoming ASCO presentations may enhance visibility for partner assets.
• Impact of AI on Demand: The increasing use of AI in drug discovery is viewed as a positive trend that could boost demand for OmniAb's platforms, particularly in data generation.
• Academic vs. Industry Partnerships: Academic deals are structured to share revenue and support asset monetization, which may differ from industry-focused agreements.
• Program Additions: The recent quarter saw fewer new program starts, attributed to standard fluctuations rather than significant market headwinds.

Overall, OmniAb reported a strong start to 2026, with significant advancements in technology and partner programs, while also providing a cautiously optimistic outlook amid some industry challenges.